This is a multifaceted, interdisciplinary program whose objectives are the elucidation of the mechanisms by which three human herpes viruses, i.e., herpes simplex virus 1, herpes simplex virus 2, and Epstein-Barr virus, replicate, maintain themselves in latent infection, and transform cells. The facility also serves as the center for teaching predoctoral and postdoctoral trainees supported by a training grant from the National Cancer Institute and by individual fellowship grants from such sources as National Institutes of Health, the American Cancer Society, Damon Runyon-Walter Winchell Foundation, and the Leukemia Society. The shared facility is the Majorie B. Kovler Viral Oncology Laboratories, which has 35,000 gross sq. ft. and 18,000 net sq. ft. It was designed as a containment facility for use with hazardous virus and was built with the aid of grant from the National Cancer Institute. The facility houses the research programs of Drs. Frenkel, Kieff, Roizman and Spear. These programs currently contain approximately 16 postdoctoral trainees and fellows, 23 predoctoral students, and 20 technical personnel. The facility is fully equipped for research work in molecular virology and oncology. It contains an electron microscope with appropriate accessories, a fully equipped dark room with film developing and printing equipment, high- and low-speed centrifuges, scintillation counters, laminar flow rooms and hood, warm rooms and a cold room, an HP9000 computer with graphics and printing peripherals and terminals throughout the building, glassware washing facilities, a conference room, and miscellaneous other equipment that is shared among the various investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-15
Application #
3819719
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Girard, Romuald; Zeineddine, Hussein A; Koskimäki, Janne et al. (2018) Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res 122:1716-1721
Day, Kasey J; Casler, Jason C; Glick, Benjamin S (2018) Budding Yeast Has a Minimal Endomembrane System. Dev Cell 44:56-72.e4
Pu, Jinyue; Kentala, Kaitlin; Dickinson, Bryan C (2018) Multidimensional Control of Cas9 by Evolved RNA Polymerase-Based Biosensors. ACS Chem Biol 13:431-437
Pectasides, Eirini; Stachler, Matthew D; Derks, Sarah et al. (2018) Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov 8:37-48
Nageeb, Shaheen; Vu, Milkie; Malik, Sana et al. (2018) Adapting a religious health fatalism measure for use in Muslim populations. PLoS One 13:e0206898
Liu, Hongtao; Zha, Yuanyuan; Choudhury, Noura et al. (2018) WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol 7:1
Ferreira, Caroline M; Williams, Jesse W; Tong, Jiankun et al. (2018) Allergen Exposure in Lymphopenic Fas-Deficient Mice Results in Persistent Eosinophilia Due to Defects in Resolution of Inflammation. Front Immunol 9:2395
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24

Showing the most recent 10 out of 668 publications